Axonyx’ Phenserine Could Be First Alzheimer’s Agent Targeting Beta-Amyloid Plaques To Reach FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials for the acetylcholinesterase inhibitor are expected to complete in December 2004. Beta-amyloid is a primary therapeutic target as companies race to develop disease-modifying therapies that go beyond the symptom relief provided by current drugs. Statins and NSAIDs are also being examined for their potential to alter the course of AD.
You may also be interested in...
Axonyx’ Phenserine Fails Pivotal Alzheimer’s Trial Due To High Placebo Response
Development program for the potential disease-modifying Alzheimer’s agent will continue, the firm says. A second pivotal trial began in June 2004. Interim results from a Phase IIb mechanistic study are expected in March.
Axonyx’ Phenserine Fails Pivotal Alzheimer’s Trial Due To High Placebo Response
Development program for the potential disease-modifying Alzheimer’s agent will continue, the firm says. A second pivotal trial began in June 2004. Interim results from a Phase IIb mechanistic study are expected in March.
Novartis, Cephalon Disease-Modifying Parkinson's Drugs Near Late-Stage Development
Novartis' TCH-346 is slated to enter Phase III in the second half of the year; Cephalon/Lundbeck's CEP-1347 is in Phase II/III. Both drugs claim inhibition of neuronal cell death as the primary mechanism, but will need long-term trials for disease-modification claim.